Results 11 to 20 of about 552 (107)

Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis [PDF]

mBio, 2022
Cryptococcal Meningitis (CM) is uniformly fatal if not treated, and treatment options are limited. We previously reported on the activity of APX2096, the prodrug of the novel Gwt1 inhibitor APX2039, in a mouse model of CM.
Charles D. Giamberardino, Wiley A. Schell, Jennifer L. Tenor, Dena L. Toffaletti, Julia R. Palmucci, Choiselle Marius, Jane-Valeriane K. Boua, Quinlyn Soltow, Robert Mansbach, M. Arthur Moseley, J. Will Thompson, Laura G. Dubois, William Hope, John R. Perfect, Karen Joy Shaw   +14 more
doaj   +2 more sources

The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo. [PDF]

Med Mycol, 2023
Mycetoma is a neglected tropical disease commonly caused by the fungus Madurella mycetomatis. Standard treatment consists of extensive treatment with itraconazole in combination with surgical excision of the infected tissue, but has a low success rate ...
Konings M, Eadie K, Strepis N, Nyuykonge B, Fahal AH, Verbon A, van de Sande WWJ.   +6 more
europepmc   +4 more sources

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. [PDF]

, 2023
The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture.
Hoenigl, Martin, Egger, Matthias, Jenks, Jeffrey D, Spec, Andrej, Sprute, Rosanne, Lass-Flörl, Cornelia, Arastehfar, Amir, Krause, Robert, Thompson, George R, Prattes, Juergen, Wiederhold, Nathan, Cornely, Oliver A   +11 more
core   +2 more sources

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)

Journal of Global Antimicrobial Resistance, 2021
: Objectives: : Manogepix, the active moiety of the prodrug fosmanogepix, is a novel antifungal with activity against major fungal pathogens including Candida (except Candida krusei), Aspergillus and difficult-to-treat/rare moulds.
Michael A. Pfaller, Michael D. Huband, Robert K. Flamm, Paul A. Bien, Mariana Castanheira   +4 more
doaj   +1 more source

Structural unification of diverse transmembrane acyltransferases reveals a conserved fold for the transmembrane acyl transferase (TmAT) superfamily. [PDF]

J Biol Chem
The movement of acyl groups across biological membranes is essential for many cellular processes. One major family of proteins catalysing this reaction are the acyl transferase family 3 (AT3) proteins, which form a pore to allow acyl-CoA to penetrate the
Kinniment-Williams BE, Jurgeleviciute V, West DT, Herman R, Blaza JN, van der Woude MW, Thomas GH.   +6 more
europepmc   +2 more sources

Novel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections

Frontiers in Microbiology, 2022
Invasive fungal infections (IFIs) pose a serious clinical problem, but the antifungal arsenal is limited and has many disadvantages, such as drug resistance and toxicity.
Cheng Zhen, Hui Lu, Yuanying Jiang
doaj   +1 more source

Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum

Computational and Structural Biotechnology Journal, 2022
The emergence of resistance to first-line antimalarials, including artemisinin, the last effective malaria therapy in some regions, stresses the urgent need to develop new effective treatments against this disease.
Àngel Fenollar, Albert Ros-Lucas, María Pía Alberione, Nieves Martínez-Peinado, Miriam Ramírez, Miguel Ángel Rosales-Motos, Ling Y. Lee, Julio Alonso-Padilla, Luis Izquierdo   +8 more
doaj   +1 more source

Our current clinical understanding of Candida biofilms: where are we two decades on?

APMIS, Volume 131, Issue 11, Page 636-653, November 2023., 2023
Clinically we have been aware of the concept of Candida biofilms for many decades, though perhaps without the formal designation. Just over 20 years ago the subject emerged on the back of progress made from the bacterial biofilms, and academic progress pace has continued to mirror the bacterial biofilm community, albeit at a decreased volume.
Gordon Ramage, Elisa Borghi, Célia Fortuna Rodrigues, Ryan Kean, Craig Williams, Jose Lopez‐Ribot   +5 more
wiley   +1 more source

Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices

APMIS, Volume 131, Issue 11, Page 654-667, November 2023., 2023
The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID‐19) infection.
Sarah Gaffney, Dearbhla M. Kelly, Puteri Maisarah Rameli, Eoin Kelleher, Ignacio Martin‐Loeches   +4 more
wiley   +1 more source

A One Health approach to overcoming fungal disease and antifungal resistance

WIREs Mechanisms of Disease, Volume 15, Issue 4, July/August 2023., 2023
A One Health approach to fungal disease integrates environment, animal, and human health to uncover new antifungal therapies and overcome the increasing threat of antifungal resistance. Abstract The global burden of fungal disease poses a substantial threat to human, animal, and environmental health, endangering both human and livestock populations and
Michael Woods, Jason A. McAlister, Jennifer Geddes‐McAlister   +2 more
wiley   +1 more source